The AI in biotechnology market size is projected to reach USD 22.72 billion by 2035, from USD 4.16 billion in 2025, at a CAGR of 18.5% during the forecast period.
The AI in biotechnology market includes technologies that use artificial intelligence to advance drug discovery, genomics, and personalized medicine. This market is defined by the growing utilization of machine learning and data analytics to improve research and development efficiency.
KEY TAKEAWAYS
- The North American AI in biotechnology market accounted for a 42.6% revenue share in 2024.
- By offering, the end-to-end solutions segment is set to register the highest CAGR of 19.9%.
- By function, the research & development segment is projected to grow at the highest rate from 2025 to 2035.
- By deployment mode, the cloud-based segment is poised to dominate the market.
- By end user, pharmaceutical companies accounted for the largest share, 36.2%, in 2024.
- NVIDIA, Illumina, Inc., and Recursion are key leaders in the global AI in biotechnology market, recognized for their extensive product portfolios, robust data integration capabilities, and strong presence across healthcare ecosystems.
The AI in biotechnology market is steadily expanding, driven by growing investments in digital transformation and the increasing focus on data-driven drug discovery, genomics, and precision medicine in the US and EU. Advances in machine learning, predictive analytics, and automation are enhancing research efficiency, biomarker identification, and therapeutic development. Moreover, strategic collaborations between biotech firms, AI solution providers, and research institutions are fostering innovation and enabling more integrated, scalable, and intelligent biotechnology workflows.
MARKET DYNAMICS
DRIVERS
– Growing cross-industry collaborations and partnerships
– Growing need to reduce time and cost of drug discovery and development
– Rising adoption of AI in precision medicine
– Improving computing power and declining hardware cost
RESTRAINTS
– High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies
– Data privacy risks and compliance challenges for AI in biotechnology
OPPORTUNITIES
– Integrating AI and big data in precision medicine for biotechnology advancement
– Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations
– Innovation across healthcare, agriculture, and environmental science for global growth
CHALLENGES
– Data quality and interpretability issues that hinder AI integration and trustworthiness
– AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges
“North America dominated the AI in biotechnology market in 2024.”
In 2024, North America reinforced its position as the leading region in the AI in biotechnology market, driven by the presence of a large number of established biotechnology and pharmaceutical companies, substantial R&D investments, and advanced technological infrastructure. The region’s strong focus on precision medicine, drug discovery, and genomics research, coupled with supportive government initiatives and widespread adoption of AI-powered platforms, further accelerates market growth. Additionally, collaborations between AI solution providers and life science organizations enhance innovation and strengthen North America’s dominance in the global AI in Biotechnology landscape. The growing availability of high-quality genomic and clinical data, along with skilled AI professionals, further supports the rapid deployment and scalability of AI solutions across the region.
Key Players
The key players functioning in the AI in biotechnology market include NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schrödinger, Inc. (US), BenevolentAI (UK), Data4Cure, Inc. (US), Qiagen (Germany), Insilico Medicine (US), DNAnexus, Inc. (US), Tempus (US), SOPHiA GENETIC (Switzerland), Predictive Oncology (US), Deep Genomics (Canada), NuMedii, Inc. (US), XtalPi Inc. (China), Iktos (France), BPGbio, Inc. (US), Eurofins Discovery (US), VeriSIM Life (US), Lifebit (UK), Verge Genomics (US), Logica (US), American Chemical Society (US), and Aganitha AI Inc. (India).
RECENT DEVELOPMENTS
- January 2025 : NVIDIA introduced Project DIGITS, a personal AI supercomputer powered by the new NVIDIA GB10 Grace Blackwell Superchip. Offering 1 petaflop of AI performance, the system would enable researchers, developers, and students to run models with up to 200 billion parameters on a desktop. Designed for energy efficiency, it supports prototyping, fine-tuning, and deployment of AI applications seamlessly across local systems, cloud, and data centers.
- January 2025 : Illumina launched a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The program utilized the upcoming Illumina Protein Prep solution to generate high-quality proteomics data, advancing biological insights and facilitating biomarker discovery for conditions like cancer and cardiovascular disease.
- July 2024 : Schrödinger, Inc. initiated an expansion of its computational platform to predict toxicology risks early in drug discovery. This initiative, funded by a USD 10 million grant from the Bill & Melinda Gates Foundation, aims to enhance drug candidate properties while reducing the risks of development failure associated with off-target protein binding.
